Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...
The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib (Tagrisso) will respond to therapy. But acquired resistance to the tyrosine kinase ...
Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies. Panelists discuss how resistance to EGFR tyrosine kinase ...
The combination of amivantamab and lazertinib shows lower EGFR and MET resistance, offering an advantage over osimertinib alone. Personalized treatment strategies are essential, considering resistance ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer. This ...
Cohort 1, osimertinib monotherapy. Cohort 2, a combination of osimertinib and savolitinib therapy. The cutoff date: May 28, 2024. FAS, Full Analysis Set; PD, Progressive disease. [1] Patients with MET ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Treatment for EGFR-Sensitive Mutation NSCLCNumerous EGFR-TKIs are approved for EGFR-sensitive mutation NSCLC, including gefitinib, erlotinib ...
The EGFR family consists of four different members: EGFR; human epidermal growth factor receptor (HER) 2; HER3; and HER4. Upon ligand binding, these receptors can homodimerize or heterodimerize with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results